SIOP PNET5 MB trial

• Verfasst von: Mynarek, Martin [VerfasserIn]
• Verfasst von: Milde, Till [VerfasserIn]
• Verfasst von: Padovani, Laetitia [VerfasserIn]
• Verfasst von: Janssens, Geert O. [VerfasserIn]
• Verfasst von: Kwiecien, Robert [VerfasserIn]
• Verfasst von: Mosseri, Veronique [VerfasserIn]
• Verfasst von: Clifford, Steven C. [VerfasserIn]
• Verfasst von: Doz, François [VerfasserIn]
• Verfasst von: Rutkowski, Stefan [VerfasserIn]
• Titel: SIOP PNET5 MB trial
• Titelzusatz: history and concept of a molecularly stratified clinical trial of risk-adapted therapies for standard-risk medulloblastoma
• Verf.angabe: Martin Mynarek, Till Milde, Laetitia Padovani, Geert O. Janssens, Robert Kwiecien, Veronique Mosseri, Steven C. Clifford, François Doz and Stefan Rutkowski
• E-Jahr: 2021
• Jahr: 2 December 2021
• Umfang: 16 S.
• Fussnoten: Gesehen am 02.09.2022
• Titel Quelle: Enthalten in: Cancers
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2021
• Band/Heft Quelle: 13(2021), 23, Artikel-ID 6077, Seite 1-16
• ISSN Quelle: 2072-6694
• DOI: doi:10.3390/cancers13236077
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: brain tumour
• Sach-SW: children
• Sach-SW: CNS
• Sach-SW: medulloblastoma
• Sach-SW: trial
• K10plus-PPN: 1815690194

Abstract

Background. SIOP PNET5 MB was initiated in 2014 as the first European trial using clinical, histological, and molecular parameters to stratify treatments for children and adolescents with standard-risk medulloblastoma. Methods. Stratification by upfront assessment of molecular parameters requires the timely submission of adequate tumour tissue. In the standard-risk phase-III cohort, defined by the absence of high-risk criteria (M0, R0), pathological (non-LCA), and molecular biomarkers (MYCN amplification in SHH-MB or MYC amplification), a randomized intensification by carboplatin concomitant with radiotherapy is investigated. In the LR stratum for localized WNT-activated medulloblastoma and age <16 years, a reduction of craniospinal radiotherapy dose to 18 Gy and a reduced maintenance chemotherapy are investigated. Two additional strata (WNT-HR, SHH-TP53) were implemented during the trial. Results. SIOP PNET5 MB is actively recruiting. The availability of adequate tumour tissue for upfront real-time biological assessments to assess inclusion criteria has proven feasible. Conclusion. SIOP PNET5 MB has demonstrated that implementation of biological parameters for stratification is feasible in a prospective multicentre setting, and may improve risk-adapted treatment. Comprehensive research studies may allow assessment of additional parameters, e.g., novel medulloblastoma subtypes, and identification and validation of biomarkers for the further refinement of risk-adapted treatment in the future.